Background: Increased spherical aberration of the cornea is a common finding after excimer laser keratorefractive keratectomy. The shape of the paracentral cornea is probably related to the incidence of side effects like glare and halos at night depending on ablation zone size and pupil diameter. Aspheric curvature changes of the paracentral cornea at the edge of the ablation may decrease those side effects.
Materials And Methods: Fifteen patients were treated with photorefractive keratectomy for myopia correction with a Summit excimer laser (Summit Technology, Waltham, Mass), one eye using a standard spherical algorithm and the fellow eye using a new aspherical algorithm. Eyes were followed for 6 to 18 months.
Results: None of 15 patients reported halos in the aspherically corrected eye stronger than in the fellow eye, whereas five patients claimed stronger halos in the spherically corrected eye. The effective clear zone size was 3.16 +/- 0.35 mm in the spherical cases compared to 3.43 +/- 0.31 in the aspherical cases, although the same ablation zone diameters of 5 mm were used. This difference is highly statistically significant. Effective spherical aberration based on raytracing analysis of the central 5 mm of the corneal topographic maps was significantly smaller in the corneas with aspheric correction than in those with spheric corrections.
Conclusion: These results indicate better optical homogeneity in eyes after aspheric photorefractive keratectomy for myopia compared to standard spherical corrections.
Download full-text PDF |
Source |
---|
Exp Eye Res
January 2025
Department of Ophthalmology, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address:
The study aimed to compare the effects of different types of excimer laser keratectomy on rabbit corneas and to identify the optimal disease model for corneal ectasia. Additionally, investigating the structural and molecular alterations in the novel disease model helped explore the mechanisms underlying biomechanical cues in corneal ectasia. 2.
View Article and Find Full Text PDFGenes (Basel)
January 2025
The Cornea Dystrophy Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemungu, Seoul 03722, Republic of Korea.
(1) Background: The phenotypes of classic lattice corneal dystrophy (LCD) and granular corneal dystrophy type 2 (GCD2) that result from abnormalities in gene () have previously been described. The phenotype of compound heterozygous classic LCD and GCD2, however, has not yet been reported. (2) Case report: A 39-year-old male (proband) presented to our clinic complaining of decreased vision bilaterally.
View Article and Find Full Text PDFCornea
January 2025
Institut für Refraktive und Ophthalmo-Chirurgie (IROC), Zurich, Switzerland.
Purpose: To describe a three-phase surgical approach for managing progressive visual decline in a patient with myopia magna and a history of epikeratophakia.
Methods: A 55-year-old woman with previous epikeratophakia surgery in both eyes experienced progressive visual deterioration. The three-phase approach included: (1) removal of the epikeratophakia lenticule, (2) cataract extraction with intraocular lens implantation, and (3) transepithelial topography-guided photorefractive keratectomy (trans-PRK).
Cureus
December 2024
Department of Ophthalmology, The University of Jordan, Amman, JOR.
We present the case of a 23-year-old male who experienced vision loss in his left eye 15 months after undergoing bilateral transepithelial photorefractive keratectomy (T-PRK). Despite the absence of any significant preoperative topographical risk factors in either eye, corneal ectasia was later confirmed in the left eye, while the right eye remained normal. Subtle asymmetry in topometric indices and a borderline high Index of vertical asymmetry (IVA) reading suggested the possibility of early subclinical keratoconus, potentially increasing the risk of post-refractive ectasia.
View Article and Find Full Text PDFBiomed Pharmacother
January 2025
The Cole Eye Institute, The Cleveland Clinic, Cleveland, OH 44195, United States. Electronic address:
Several studies in rabbits demonstrated the efficacy and safety of topical losartan, an angiotensin II receptor blockers (ARB) that modulates the TGF-β intracellular signaling pathways by inhibiting the activation of Extracellular Signal-regulated Kinase (ERK), in preventing or treating stromal fibrosis after a range of injuries such as Descemetorhexis, alkali burns, incisions, and photorefractive keratectomy (PRK). Several case reports have shown that topical losartan treatment is also efficacious and safe in humans to prevent or treat stromal fibrosis after many different injuries or diseases. Topical losartan penetrates the full thickness of the cornea and, therefore, can treat both anterior and posterior stromal fibrosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!